Suppr超能文献

分析新冠肺炎康复患者的麻疹-腮腺炎-风疹(MMR)滴度。

Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.

机构信息

World Organization, Watkinsville, Georgia, USA

Nevada Spine Center, Las Vegas, Nevada, USA.

出版信息

mBio. 2020 Nov 20;11(6):e02628-20. doi: 10.1128/mBio.02628-20.

Abstract

The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against coronavirus disease 2019 (COVID-19). Our aim was to determine whether any MMR IgG titers are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with MMR II. We divided 80 subjects into two groups, comparing MMR titers to recent COVID-19 severity levels. The MMR II group consisted of 50 subjects who would primarily have MMR antibodies from the MMR II vaccine, and a comparison group of 30 subjects consisted of those who would primarily have MMR antibodies from sources other than MMR II, including prior measles, mumps, and/or rubella illnesses. There was a significant inverse correlation (  = -0.71,  < 0.001) between mumps virus titers (mumps titers) and COVID-19 severity within the MMR II group. There were no significant correlations between mumps titers and severity in the comparison group, between mumps titers and age in the MMR II group, or between severity and measles or rubella titers in either group. Within the MMR II group, mumps titers of 134 to 300 arbitrary units (AU)/ml ( = 8) were found only in those who were functionally immune or asymptomatic; all with mild symptoms had mumps titers below 134 AU/ml ( = 17); all with moderate symptoms had mumps titers below 75 AU/ml ( = 11); all who had been hospitalized and had required oxygen had mumps titers below 32 AU/ml ( = 5). Our results demonstrate that there is a significant inverse correlation between mumps titers from MMR II and COVID-19 severity. COVID-19 has presented various paradoxes that, if understood better, may provide clues to controlling the pandemic, even before a COVID-19 vaccine is widely available. First, young children are largely spared from severe disease. Second, numerous countries have COVID-19 death rates that are as low as 1% of the death rates of other countries. Third, many people, despite prolonged close contact with someone who is COVID-19 positive, never test positive themselves. Fourth, nearly half of people who test positive for COVID-19 are asymptomatic. Some researchers have theorized that the measles-mumps-rubella (MMR) vaccine may be responsible for these disparities. The significance of our study is that it showed that mumps titers related to the MMR II vaccine are significantly and inversely correlated with the severity of COVID-19-related symptoms, supporting the theorized association between the MMR vaccine and COVID-19 severity.

摘要

麻疹-腮腺炎-风疹(MMR)疫苗被认为可以预防 2019 年冠状病毒病(COVID-19)。我们的目的是确定先前接种过 MMR II 的 COVID-19 康复患者中,任何 MMR IgG 滴度是否与严重程度呈负相关。我们将 80 名受试者分为两组,比较 MMR 滴度与近期 COVID-19 严重程度。MMR II 组包括 50 名主要来自 MMR II 疫苗的 MMR 抗体的受试者,对照组包括 30 名主要来自 MMR II 以外来源的 MMR 抗体的受试者,包括既往麻疹、腮腺炎和/或风疹感染。在 MMR II 组中,腮腺炎病毒滴度(腮腺炎滴度)与 COVID-19 严重程度之间存在显著负相关(  = -0.71,  < 0.001)。在对照组中,腮腺炎滴度与严重程度之间没有显著相关性,在 MMR II 组中,腮腺炎滴度与年龄之间也没有显著相关性,在两组中,严重程度与麻疹或风疹滴度之间也没有显著相关性。在 MMR II 组中,仅在功能免疫或无症状的患者中发现腮腺炎滴度为 134 至 300 个任意单位(AU)/ml(  = 8);所有症状轻微的患者腮腺炎滴度均低于 134 AU/ml(  = 17);所有中度症状的患者腮腺炎滴度均低于 75 AU/ml(  = 11);所有住院并需要吸氧的患者腮腺炎滴度均低于 32 AU/ml(  = 5)。我们的结果表明,MMR II 中的腮腺炎滴度与 COVID-19 严重程度之间存在显著负相关。COVID-19 提出了各种悖论,如果能更好地理解这些悖论,即使在 COVID-19 疫苗广泛可用之前,也可能为控制大流行提供线索。首先,幼儿在很大程度上免受严重疾病的影响。其次,许多国家的 COVID-19 死亡率与其他国家的死亡率一样低,低至 1%。第三,许多人尽管与 COVID-19 阳性患者密切接触时间较长,但自己从未检测呈阳性。第四,近一半的 COVID-19 检测呈阳性的人无症状。一些研究人员推测,麻疹-腮腺炎-风疹(MMR)疫苗可能对此负责。我们研究的意义在于,它表明与 MMR II 疫苗相关的腮腺炎滴度与 COVID-19 相关症状的严重程度呈显著负相关,支持了 MMR 疫苗与 COVID-19 严重程度之间的理论关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e9a/7686805/0b404e2dfffe/mBio.02628-20-f0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验